RESUMEN
Psoriasis is an autoimmune and inflammatory skin disease. Psoriatic patients express higher levels of plasma homocysteine (Hcy) concentration and pro-inflammatory mediators than healthy people; this is frequently associated with vitamin D deficiency. The aim of this clinical study was to investigate the effects of high doses of vitamin D supplementation on the parameters of Hcy metabolism and cytokines in sera of psoriatic patients. This prospective study was conducted on 40 psoriatic patients who had the vitamin D deficiency. All patients received vitamin D 5000 IU/day for three months. Clinical and biochemical measurements were taken at baseline and at follow up (3 months). The results showed that the severity of clinical features, measured by the psoriasis area severity index (PASI) score, were considerably improved in patients after vitamin D supplementation. After vitamin D supplementation, most of the patients (n = 25 or 62.5%) had mild clinical form (p < 0.001). After twelve weeks of intervention period, there were significant increases in vitamin D and B12 serum levels in comparison to the levels that had been measured at the beginning of the study (56.77 ± 14.66 nmol/L and 301.08 ± 95.02 pg/mL vs. 103.85 ± 32.20 nmol/L and 362.81 ± 118.56 pg/mL, respectively; p < 0.001). Moreover, serum levels of Hcy and folate were significantly lower at the end of the study in comparison with the initial levels (12.45 ± 1.92 µmol/L and 8.01 ± 3.88 mg/mL vs. 10.38 ± 1.66 µmol/L and 6.27 ± 2.60 mg/mL, respectively). High doses of vitamin D supplementation led to a significant decrease in pro-inflammatory cytokines (IFN-ɤ, TNF-α, IL-1ß, IL-6, IL-8, and IL-17) and high-sensitivity C-reactive protein (hsCRP), whereas the production of anti-inflammatory cytokines (IL-10, IL-5) was up-regulated. In conclusion, supplementation with high doses of vitamin D could be one of the possible preventive and therapeutic measures to reduce systemic inflammation in psoriatic patients.
Asunto(s)
Citocinas/sangre , Homocisteína/sangre , Psoriasis/tratamiento farmacológico , Deficiencia de Vitamina D/tratamiento farmacológico , Vitamina D/administración & dosificación , Adulto , Anciano , Biomarcadores/sangre , Citocinas/efectos de los fármacos , Suplementos Dietéticos , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Homocisteína/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Gravedad del Paciente , Estudios Prospectivos , Psoriasis/sangre , Vitamina B 12/sangre , Vitamina D/farmacología , Deficiencia de Vitamina D/sangreRESUMEN
INTRODUCTION: Previous studies have suggested a significant increase in plasma homocysteine (Hcy) levels in levodopa-treated Parkinson's disease (PD) patients, and vitamin B12 and folate supplementation may decrease Hcy levels. However, the effects of catechol-O-methyltransferase inhibitors on levodopa-induced increase in Hcy levels were conflicting. The aim of this study was to evaluate whether Hcy levels are increased in levodopa-treated PD patients and to evaluate the effects of vitamin B12 and folate or entacapone on Hcy levels in levodopa-treated PD patients. METHODS: We analyzed and compared plasma Hcy levels in 20 levodopa-naïve PD patients and 42 levodopa-treated PD patients, followed by randomized assignment of 42 levodopa-treated patients to treatment groups with either vitamin B12 and folate, entacapone, or no medication. RESULTS: Plasma Hcy levels in levodopa-treated PD patients were higher than those in the control group, but the difference was not statistical significant (15.25 ± 6.70 and 13.13 ± 4.68, P = 0.216). Patients treated with vitamin B12 and folate had a significant decrease in plasma Hcy levels (P < 0.001). In the entacapone group, Hcy levels were mildly decreased, but the change did not reach statistical significance. CONCLUSION: Levodopa-treated PD patients had higher plasma Hcy than levodopa-naive PD patients. Unlike entacapone, combination supplementation with vitamin B12 and folate was associated with significantly decreased plasma Hcy. We suggest that plasma Hcy levels should be monitored during levodopa treatment, and supplementation with inexpensive vitamin B12 and folate is beneficial for levodopa-treated patients.
Asunto(s)
Antiparkinsonianos/uso terapéutico , Catecoles/uso terapéutico , Homocisteína/sangre , Nitrilos/uso terapéutico , Enfermedad de Parkinson/sangre , Enfermedad de Parkinson/tratamiento farmacológico , Anciano , Femenino , Ácido Fólico/uso terapéutico , Homocisteína/efectos de los fármacos , Humanos , Hiperhomocisteinemia/inducido químicamente , Hiperhomocisteinemia/prevención & control , Levodopa/uso terapéutico , Masculino , Persona de Mediana Edad , Proyectos de Investigación , Vitamina B 12/uso terapéuticoRESUMEN
This study aimed to evaluate the effect of two doses of cyclohexane extract of walnut leaves on total homocysteine, lipids profiles, and indices of oxidative stress including superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), and malondialdehyde (MDA) in diabetic rats. Diabetes was induced by a single intraperitoneal (IP) injection of streptozotocin (50 mg/kg BW). Twenty-eight male Sprague Dawley rats were randomly divided into four groups, group I: control (received sesame oil as vehicle), group II: diabetic control (received sesame oil), group III and IV: diabetic rats treated by 150 and 250 mg/kg body weight (BW) per day extract of walnut leaves, respectively. All groups were treated for 28 days via oral gavage. Fasting blood glucose (FBG) level and body weight measured before injection, 3 days after injection, and on days 0, 7, 14, 21, and 28 of treatment. At the end the 28th day of the experiment, blood samples collected via heart puncture and the sera were used for estimation of the above-mentioned parameters. The results showed a decrease in FBS, TC, TG, LDL-c, VLDL-c, homocysteine, and MDA level and increase in the level of HDL-c in diabetics treated by walnut leave extracts in a dose-dependent manner after 28 days. The activity of antioxidant enzymes significantly increased in treated groups compared with diabetic control. It can be concluded that cyclohexane extract of walnut leaves has an overall beneficial effect on body weight, fasting blood glucose, lipids profile, antioxidant enzyme activities, and homocysteine.
Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus Experimental/metabolismo , Homocisteína/efectos de los fármacos , Juglans , Metabolismo de los Lípidos/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/farmacología , Hojas de la Planta , Animales , Glucemia/metabolismo , Catalasa/efectos de los fármacos , Catalasa/metabolismo , Colesterol/metabolismo , LDL-Colesterol/efectos de los fármacos , LDL-Colesterol/metabolismo , VLDL-Colesterol/efectos de los fármacos , VLDL-Colesterol/metabolismo , Ciclohexanos , Glutatión Peroxidasa/efectos de los fármacos , Glutatión Peroxidasa/metabolismo , Homocisteína/metabolismo , Masculino , Malondialdehído/metabolismo , Fitoterapia , Ratas , Ratas Sprague-Dawley , Superóxido Dismutasa/efectos de los fármacos , Superóxido Dismutasa/metabolismo , Triglicéridos/metabolismoRESUMEN
PURPOSE: Several studies highlighted a correlation between folic acid deficiency and high plasma homocysteine concentration, considered a risk factor for multifactorial diseases. Natural folates represent an emerging alternative strategy to supplementation with synthetic folic acid, whose effects are controversial. The present work was, therefore, performed in hyperhomocysteinemic mice to study the impact of supplementation with dairy matrices containing natural folates on plasma homocysteine levels and faecal microbiota composition. METHODS: Forty mice were divided into six groups, two of which fed control or folic acid deficient (FD) diets for 10 weeks. The remaining four groups were fed FD diet for the first 5 weeks and then shifted to a standard control diet containing synthetic folic acid (R) or a FD diet supplemented with folate-enriched fermented milk (FFM) produced by selected lactic acid bacteria, fermented milk (FM), or milk (M), for additional 5 weeks. RESULTS: Supplementation with dairy matrices restored homocysteine levels in FD mice, although impacting differently on hepatic S-adenosyl-methionine levels. In particular, FFM restored both homocysteine and S-adenosyl-methionine levels to the control conditions, in comparison with FM and M. Next generation sequencing analysis revealed that faecal microbiota of mice supplemented with FFM, FM and M were characterised by a higher richness of bacterial species in comparison with C, FD and R groups. Analysis of beta diversity highlighted that the three dairy matrices determined specific, significant variations of faecal microbiota composition, while hyperhomocysteinemia was not associated with significant changes. CONCLUSIONS: Overall, the results represent a promising starting point for the applicability of food matrices enriched in natural folates to manage hyperhomocysteinemia.
Asunto(s)
Dieta/métodos , Alimentos Fermentados , Ácido Fólico/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Homocisteína/sangre , Hiperhomocisteinemia/dietoterapia , Leche/metabolismo , Animales , Modelos Animales de Enfermedad , Homocisteína/efectos de los fármacos , Hiperhomocisteinemia/sangre , Masculino , Ratones , Ratones Endogámicos C57BLRESUMEN
BACKGROUND: Homocysteine levels are elevated in patients with type 1 diabetes mellitus (T1DM) and could induce renal injury. B vitamins have an important role in preventing microvascular complications of diabetes. AIM: We performed a randomized-controlled trial of oral supplementation with vitamin B complex as an adjuvant therapy for nephropathy in pediatric T1DM patients and assessed its relation to homocysteine and cystatin C as a marker of nephropathy. METHODS: This trial included 80 T1DM patients with microalbuminuria, despite oral angiotensin-converting enzyme inhibitors, aged 12-18 years with at least 5 years disease duration and HbA1c ≤8.5%. Patients were randomly assigned into two groups; intervention group which received oral vitamin B complex (B1, B6 and B12) once daily and placebo group. Both groups were followed-up for 12 weeks with assessment of plasma homocysteine, HbA1c, urinary albumin excretion (UAE) and cystatin C. RESULTS: Both groups were well-matched in baseline clinical and laboratory parameters. Baseline homocysteine levels were elevated in both groups compared with reference control values. After 12 weeks, supplementation with vitamin B complex for the intervention group resulted in a significant decrease of homocysteine, fasting blood glucose, HbA1c, triglycerides, total cholesterol, UAE and cystatin C compared with baseline levels (p < 0.001) and with placebo group (p < 0.001). No adverse reactions were reported. Baseline cystatin C was negatively correlated to vitamin B12 (r = -0.77, p = 0.001). CONCLUSIONS: Vitamin B complex improved glycemic control and renal function through decreasing homocysteine and could be a safe and effective strategy for treatment of early stage nephropathy in pediatric T1DM. This trial was registered at ClinicalTrials.gov (NCT03594240).
Asunto(s)
Diabetes Mellitus Tipo 1/complicaciones , Nefropatías Diabéticas/complicaciones , Nefropatías Diabéticas/tratamiento farmacológico , Suplementos Dietéticos , Homocisteína/efectos de los fármacos , Complejo Vitamínico B/uso terapéutico , Adolescente , Niño , Diabetes Mellitus Tipo 1/fisiopatología , Nefropatías Diabéticas/fisiopatología , Método Doble Ciego , Femenino , Humanos , Masculino , Estudios Prospectivos , Complejo Vitamínico B/administración & dosificaciónRESUMEN
INTRODUCTION: In recent years, there has been a sharp increase in the number of patients with neurological disorders associated with recreational use of nitrous oxide (N2O) in China. Here, we summarize the clinical characteristics of patients with neurological disorders associated with N2O abuse diagnosed in our Hospital. Further, we conducted a literature search on recent cases reported in mainland China to improve the awareness of the outbreak of neurological disorders associated with N2O abuse. METHODS: We retrospectively collected data of patients diagnosed with neurological disorders associated with recreational use of N2O in Shengjing Hospital of China Medical University from January 2018 to June 2019, and performed a literature search using the "nitrous oxide" and "neurological disorder" as keywords in the Chinese literature databases of WANFANG and CNKI and the English literature databases of Pubmed and Web of Science RESULTS: We enrolled 43 patients (average age: 21.9 ± 3.3 years). The main clinical manifestations were weakness and paresthesia in the four extremities and unsteady gait. Further, most patients showed significantly lower levels of serum vitamin B12 (169.4 ± 79.1 pg/mL) and increased homocysteine levels (78.1 ± 32.2 µmol/L). MRI of the spinal cord showed longitudinal high T2 signal lesions in the dorsal spinal cord in some patients. Moreover, electromyography showed sensory and motor nerve axonal damage combined with demyelination, which was relatively more severe in the lower limbs. There was rapid improvement of the symptoms after treatment with intramuscular injections of vitamin B12 and the overall prognosis was good. The literature search indicated that the number of published papers and related patients showed a rapid annual increase since the first Chinese case reported in 2016 CONCLUSION: Recreational use of N2O is an emerging public health problem in China that needs prompt action from the society and government. Early diagnosis and treatment allow a good overall prognosis.
Asunto(s)
Drogas Ilícitas/efectos adversos , Enfermedades del Sistema Nervioso/inducido químicamente , Óxido Nitroso/efectos adversos , Trastornos Relacionados con Sustancias/complicaciones , Adolescente , Adulto , China , Enfermedades Desmielinizantes/inducido químicamente , Femenino , Trastornos Neurológicos de la Marcha/inducido químicamente , Homocisteína/efectos de los fármacos , Humanos , Masculino , Debilidad Muscular/inducido químicamente , Enfermedades del Sistema Nervioso/sangre , Enfermedades del Sistema Nervioso/patología , Parestesia/inducido químicamente , Estudios Retrospectivos , Enfermedades de la Columna Vertebral/inducido químicamente , Enfermedades de la Columna Vertebral/patología , Vitamina B 12/sangre , Adulto JovenRESUMEN
BACKGROUND: To determine the influence of phenytoin (PHT) monotherapy on the serum levels of homocysteine (Hcy), folate and vitamin B12 in patients with epilepsy. METHODS: Literature retrieval was performed through PubMed, Web of Science, Embase, Cochrane Library, Chinese Wanfang Data, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Database databases as of the end of March 2018. Pooled weighted mean difference (WMD) and 95% CIs were calculated using a random effect model. RESULTS: A total of ten eligible studies were identified. The result revealed that the serum level of homocysteine in PHT-treated patients with epilepsy was significantly higher than that in control group (WMDâ=â8.47, 95% CI: 6.74 to 10.20, Pâ<â.001). In addition, the serum levels of folate (WMDâ=â-3.51, 95% CI: -4.20 to -2.83, Pâ<â.001) and vitamin B12 (WMDâ=â-62.23, 95% CI: -83.27 to -41.19, Pâ<â.001) were decreased significantly compared with the control group. CONCLUSIONS: Our meta-analysis indicates that PHT monotherapy is associated with the increase in the serum homocysteine levels and decreased levels of folate and vitamin B12, and hyperhomocysteinaemia may contribute to the acceleration of the atherosclerotic process. Therefore, the patients under these medications should be monitored plasma homocysteine.
Asunto(s)
Anticonvulsivantes/farmacología , Ácido Fólico/sangre , Homocisteína/sangre , Fenitoína/farmacología , Vitamina B 12/sangre , Anticonvulsivantes/uso terapéutico , Epilepsia/tratamiento farmacológico , Homocisteína/efectos de los fármacos , Humanos , Fenitoína/uso terapéutico , Proyectos de InvestigaciónRESUMEN
OBJECTIVES: This study aimed to determine whether an enhanced bioavailable curcumin formulation, CurQfen®, would improve circulating cardiovascular disease-related blood biomarkers and arterial function in young (age 18-35 y), obese (body mass index ≥ 30.0 kg/m2) men. METHODS: This double-blinded, placebo-controlled trial evaluated 22 men. The participants were matched based on body mass index and randomized to the intervention (curcumin formulated with fenugreek soluble fiber, for enhanced absorption) or control (fenugreek soluble fiber) group for 12 wk at 500mg/d without dietary modification or exercise. Blood samples and endothelial function measures were acquired at 0 and 12 wk, and blood samples were analyzed for cardiovascular disease-related blood biomarkers. Furthermore, central (aortic) blood pressure and augmentation index were monitored at 0, 4, 8, and 12 wk. RESULTS: After 12 wk of intervention, homocysteine levels were lower (curcumin before: 12.22 ± 2.29 µg/mL, after: 8.62 ± 1.02 µg/mL versus placebo before: 9.45 ± 0.84 µg/mL, after: 11.84 ± 1.63 µg/mL; Pâ¯=â¯0.04) and high-density lipoprotein levels were higher (curcumin before: 40.77 ± 5.37 mg/dL, after: 54.56 ± 11.72 mg/dL versus placebo before: 61.20 ± 5.76 mg/dL, after: 48.82 ± 5.49 mg/dL; Pâ¯=â¯0.04) in the curcumin group relative to the placebo group. However, there was no significant difference in changes between the circulating concentrations of glucose, insulin, leptin, adiponectin, or oxidative stress biomarkers in the curcumin group compared with the placebo group (P > 0.05). No changes were found with endothelial function, augmentation index, or central blood pressure in the curcumin group compared with the placebo group (P > 0.05). CONCLUSIONS: Our data provide evidence for an enhanced bioavailable curcumin to improve homocysteine and high-density lipoprotein concentrations, which may promote favorable cardiovascular health in young, obese men. Improvements in endothelial function or blood pressure were not observed with curcumin supplementation, thus further investigation is warranted.
Asunto(s)
Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/complicaciones , Curcumina/farmacología , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/fisiología , Obesidad/complicaciones , Adolescente , Adulto , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/sangre , Antiinflamatorios no Esteroideos/farmacología , Arterias/efectos de los fármacos , Arterias/fisiología , Biomarcadores/sangre , Curcumina/administración & dosificación , Curcumina/metabolismo , Suplementos Dietéticos , Método Doble Ciego , Homocisteína/sangre , Homocisteína/efectos de los fármacos , Humanos , Lipoproteínas/sangre , Lipoproteínas/efectos de los fármacos , Masculino , Obesidad/sangre , Factores de Riesgo , Adulto JovenRESUMEN
AIM: Abnormally high levels of homocysteine (Hcy) are associated with autism spectrum disorder. Betaine is a methyl group donor in Hcy metabolism, and is known to prevent noxious Hcy accumulation. This study explored whether betaine could influence Hcy metabolism in a mouse model of autism and ameliorate behavioral abnormalities. METHODS: Pregnant ICR mice were administered valproic acid (VPA) intraperitoneally on Embryonic Day 12.5. Serum Hcy concentrations in the offspring were measured by enzyme-linked immunosorbent assay. Expressions of Hcy-metabolism-related enzymes, betaine-Hcy methyltransferase, cystathionine ß-synthase, and methionine synthase, were measured by quantitative reverse transcription polymerase chain reaction and western blotting. Offspring were treated by either betaine or saline at the age of 8 weeks and serum Hcy concentrations were measured. Social behaviors were assessed by sniff-duration test and three-chamber test. Repetitive behavior was evaluated by marble-burying test. Tail-flick test was performed to measure nociceptive sensitivity. RESULTS: Prenatal VPA-exposed mice showed significantly elevated Hcy concentrations and decreased betaine-Hcy methyltransferase expression. Treatment with betaine could reduce Hcy level in VPA-exposed mice, attenuate social impairment and repetitive behavior, and normalize nociceptive sensitivity in this model. CONCLUSION: Betaine could ameliorate autism-like features and play a beneficial role in a mouse autism model induced by prenatal VPA exposure.
Asunto(s)
Antimaníacos/efectos adversos , Trastorno del Espectro Autista/prevención & control , Betaína/farmacología , Homocisteína/efectos de los fármacos , Efectos Tardíos de la Exposición Prenatal/prevención & control , Sustancias Protectoras/farmacología , Conducta Social , Ácido Valproico/efectos adversos , Animales , Antimaníacos/administración & dosificación , Trastorno del Espectro Autista/sangre , Trastorno del Espectro Autista/inducido químicamente , Conducta Animal/efectos de los fármacos , Betaína/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Homocisteína/sangre , Ratones , Ratones Endogámicos ICR , Embarazo , Efectos Tardíos de la Exposición Prenatal/sangre , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Sustancias Protectoras/administración & dosificación , Ácido Valproico/administración & dosificaciónRESUMEN
In various metabolic diseases, both the coronary circulation and cardiac metabolism are altered. Here we summarize the effects of a condition called hyperhomocysteinemia (HHcy) - which can develop due to genetic and/or environmental causes - on the function of coronary microvessels and heart. This metabolic disease is underappreciated, yet even mild or moderate elevation of plasma concentrations of homocystein (Hcy, plasma Hcy >16 µM), a sulfur-containing amino acid produced via methionine metabolism) leads to coronary and peripheral artery and even venous vessel diseases, eliciting vasomotor dysfunction and increased thrombosis, consequently increased morbidity and mortality. Yet the underlying mechanisms have not yet been revealed. Recent studies indicated that there are common pathomechanisms, which may affect several cellular functions. With methionin diet-induced HHcy two main pathomechanisms were revealed: the dysfunction of nitric oxide (NO) pathway resulting in reduced dilator responses of arteries and arterioles, and the simultaneously increased thromboxane A2 (TXA2) activity both in vessels and platelets. These changes are likely due to an increased production of reactive oxidative species (oxidative stress) due to increased NADPH oxidase assembly, which eventually lead to inflammatory processes (indicated by increases in TNFα, NFκbeta, p22phox, p67phox, and rac-1, levels) and changes in various gene expressions and morphological remodeling of vessels. Increased superoxide production and reduced availability of NO alter the regulation of mitochondrial function in the myocardium. The interactions of these pathomechanisms may explain why HHcy increases the uptake of glucose and lactate and decreases the uptake of free fatty acid by the heart. The pathological consequences of HHcy could be worsening by the simultaneous presence of other risk factors, such as hyperlipidemia, diabetes mellitus and metabolic syndrome. All in all, HHcy and associated pathometabolism lead to severe changes and dysfunctions of coronary arterial vessels and cardiac function, which may not always be apparent in clinical settings but most likely contribute to the increased prevalence of cardiovascular diseases and mortality, which however can be reduced by appropriate prevention and treatments. We believe that HHcy is an underestimated - likely due to inappropriate clinical trials - but serious disease condition because it promotes the development of atherosclerosis in large arterial vessels, vasomotor dysfunction in microvessels, hypertension and thrombosis. In this review, we will summarize previous functional findings focusing on coronary vessels and cardiac function and the underlying cellular and molecular mechanisms enabling the development of novel treatments.
Asunto(s)
Enfermedades Cardiovasculares/metabolismo , Vasos Coronarios/metabolismo , Homocisteína/metabolismo , Animales , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/patología , Muerte Celular/efectos de los fármacos , Vasos Coronarios/efectos de los fármacos , Vasos Coronarios/patología , Homocisteína/sangre , Homocisteína/efectos de los fármacos , Humanos , Fármacos Neuroprotectores/farmacologíaRESUMEN
OBJECTIVE: This study was designed to evaluate the effects of 3 mg drospirenone/30 µg ethinyl estradiol (OC) alone or combined with 1700 mg metformin on metabolic risk factors. MATERIALS AND METHODS: In this randomized, prospective, controlled study, 87 non-obese (18-30 BMI) women of reproductive age (18-39) with polycystic ovary syndrome (PCOS) were assigned to control (n = 17), OC (n = 21), combination (n = 20) and metformin (n = 29) therapy groups. RESULTS: Adiponectin levels changed -28.27%, -20.37% and 35.78% after OC, combination and metformin therapies, respectively. High sensitive C-reactive protein levels (hsCRP) changed with OC, combination and metformin therapies by 102.32%, 3.2% and -7.14%, respectively. Plasminogen activator inhibitor-1 levels decreased 41.34% in the metformin group. Apolipoprotein-B levels changed in a manner similar to changes in hsCRP levels. The homeostatic model insulin resistance index changed significantly between the groups following treatment (p = 0.001). CONCLUSION: Six cycles of treatments with OC alone may cause metabolic variables to deteriorate in non-obese women with PCOS. The addition of metformin to OC may ameliorate some aspects of this effect.
Asunto(s)
Apolipoproteínas B/efectos de los fármacos , Glucemia/metabolismo , Proteína C-Reactiva/efectos de los fármacos , Resistencia a la Insulina , Fragmentos de Péptidos/efectos de los fármacos , Inhibidor 1 de Activador Plasminogénico/efectos de los fármacos , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Adulto , Androstenos/administración & dosificación , Apolipoproteínas B/metabolismo , Glucemia/efectos de los fármacos , Enfermedades Cardiovasculares/etiología , Quimioterapia Combinada , Etinilestradiol/administración & dosificación , Femenino , Homocisteína/efectos de los fármacos , Humanos , Hipoglucemiantes/administración & dosificación , Síndrome Metabólico/prevención & control , Metformina/administración & dosificación , Antagonistas de Receptores de Mineralocorticoides/administración & dosificación , Fragmentos de Péptidos/metabolismo , Inhibidor 1 de Activador Plasminogénico/metabolismo , Síndrome del Ovario Poliquístico/complicaciones , Sustancias para el Control de la Reproducción/administración & dosificación , Factores de Riesgo , Adulto JovenRESUMEN
BACKGROUND: Long-term antiepileptic drug (AED) therapy has been associated with metabolic consequences that lead to an increase in risk of atherosclerosis in patients with epilepsy. Earlier published studies showed conflicting results about the levels of hematological parameters, serum homocysteine, folate, and vitamin B12, in epileptics treated with phenytoin monotherapy. Therefore, we evaluated homocysteine metabolism and hematological parameters in early stage of phenytoin treated epileptic children. METHODS: A total of 64 newly diagnosed epileptic children with mean age 10.09 ± 2.56 years were enrolled at the start of study. However, after 3 months follow up, the final total sample size was only 50 epileptic children. Fourteen children dropped out of study due to poor follow up. Serum homocysteine levels were measured by enzyme immunoassay method. Serum folate and vitamin B12 levels were estimated by Competitive Chemiluminescent Enzyme Immunoassay method. Hematological parameters were analysed by an automated hematology analyzer (Cell counter), Sysmex XT-1800i, using commercially available reagents. RESULTS: In our study the anthropometric and hematological parameters did not show any significant difference after phenytoin monotherapy as compared to before therapy in epileptic children. The serum homocysteine level in epileptic children was found to be significantly increased after phenytoin (PHT) monotherapy as compared to before therapy. Moreover, a highly significant decrease was observed in the serum folate and vitamin B12 levels after phenytoin monotherapy as compared to before therapy in epileptic children. CONCLUSIONS: Phenytoin monotherapy may cause a significant increase in the levels of serum homocysteine and a significant decrease in the serum folate and vitamin B12 levels in children with epilepsy, and the significant changes in above mentioned parameters occur early in the course of treatment. This could be responsible for a higher prevalence of cardiovascular incidents in epileptic children taking phenytoin monotherapy. Therefore, it may be useful to do early screening and treatment of increased serum homocysteine levels in epileptic children under phenytoin monotherapy to prevent atherosclerosis and its complications. Hematological parameters should also be strictly monitored regularly in individuals administered with PHT monotherapy. If there are persistent alterations, the administration of the drugs should be discontinued.
Asunto(s)
Anticonvulsivantes/efectos adversos , Epilepsia/tratamiento farmacológico , Homocisteína/efectos de los fármacos , Fenitoína/efectos adversos , Carbamazepina , Niño , Femenino , Ácido Fólico , Homocisteína/metabolismo , Humanos , Masculino , Vitamina B 12RESUMEN
Increase in serum homocysteine is shown to be a potential risk factor for cognitive impairment. Evidence suggests that vitamin B supplementation may reduce cognitive decline by lowering the homocysteine levels. The current meta-analysis evaluated the efficacy of folic acid along with vitamin B12 and/or B6 in lowering homocysteine, thereby attenuating cognitive decline in elderly patients with Alzheimer disease or dementia. Randomized controlled trials (RCTs) comparing the efficacy of folate and B vitamin supplementation in patients with cognitive decline secondary to Alzheimer disease or dementia were identified using the keywords, "homocysteine, hyper-homocysteinemia, B vitamin, vitamin B6, B12, folic acid, cognitive, Alzheimer's disease, and dementia." The outcome measures analyzed were the Mini-Mental State Examination (MMSE) score and serum homocysteine. Of the 77 studies identified, 4 RCTs were included in the current meta-analysis. The baseline characteristics, age, and gender distribution of patients among the 2 groups (supplement vs placebo) were comparable. The results reveal that the intervention group achieved significantly greater reduction in homocysteine levels than the control (pooled difference in means = -3.625, 95% confidence interval [CI] = -5.642 to -1.608, P < .001). However, no significant difference in MMSE (pooled difference in means = 0.027, 95% CI = -0.518 to 0.573, P = 0.921) was observed between the groups. Taken together, vitamin B supplementation was effective in reducing serum homocysteine levels. However, it did not translate into cognitive improvement, indicating that the existing data on vitamin B-induced improvement in cognition by lowering homocysteine levels are conflicting.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Trastornos del Conocimiento/tratamiento farmacológico , Cognición/efectos de los fármacos , Demencia/tratamiento farmacológico , Ácido Fólico/uso terapéutico , Homocisteína/sangre , Vitamina B 12/uso terapéutico , Vitamina B 6/uso terapéutico , Complejo Vitamínico B/uso terapéutico , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/etiología , Trastornos del Conocimiento/sangre , Trastornos del Conocimiento/etiología , Demencia/etiología , Suplementos Dietéticos , Quimioterapia Combinada , Femenino , Ácido Fólico/sangre , Homocisteína/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Vitamina B 12/sangre , Vitamina B 6/sangre , Complejo Vitamínico B/sangreRESUMEN
To investigate whether α-tocopherol supplementation in workers exposed to lead would reduce the oxidative stress intensity and decrease homocysteine level, the examined population was randomly divided into two groups. Workers in the first group (n = 49, reference group) were not administered any drugs. Workers in the second group (n = 34) were administered orally α-tocopherol, 200 mg per day for 12 weeks. The level of α-tocopherol significantly increased compared to the baseline and the reference group. The level of thiol groups significantly increased compared to the reference group. However, the levels of malondialdehyde and homocysteine did not significantly change. Animal studies suggest the ability of α-tocopherol administration to reverse adverse health effects of lead exposure, such as oxidative stress; however, the results of this study on humans do not confirm these protective effects.
Asunto(s)
Antioxidantes/administración & dosificación , Antioxidantes/farmacología , Homocisteína/efectos de los fármacos , Intoxicación por Plomo/complicaciones , Exposición Profesional , Estrés Oxidativo/efectos de los fármacos , alfa-Tocoferol/administración & dosificación , alfa-Tocoferol/farmacología , Adulto , Homocisteína/sangre , Humanos , Persona de Mediana EdadRESUMEN
OBJECTIVES: Vitamin B-12 and n-3 polyunsaturated fatty acids (PUFA) decrease blood homocysteine (Hcy) concentrations. However, the combined effect of these nutrients on Hcy and ferritin, and C-reactive protein is limited and inconclusive. The objective was to examine the synergistic effect of vitamin B-12 in combination of n-3 PUFA on plasma Hcy, ferritin, and other biochemical markers. METHODS: In a randomized controlled trial, thirty eligible subjects were randomly divided into three groups, and assigned to receive 1000 µg of vitamin B-12, 2 g fish oil, or 1000 µg vitamin B-12 and 2 g fish oil, respectively, for 8 weeks. Plasma phospholipids (PL) fatty acids and biochemical markers were determined. This study was registered under ClinicalTrials.gov Identifier: NCT01762072. RESULTS: Plasma PL 20:5n-3, 22:6n-3 and n-3 PUFA was increased after 4 and 8 week supplementation of fish oil, and vitamin B-12+fish oil. Plasma concentrations of triacylglycerol, uric acid, C-reactive protein, and ferritin were significantly decreased after 4 and 8 week supplementation of fish oil, and vitamin B-12+fish oil. In all groups, significant changes in plasma Hcy were observed during the study period. Vitamin B-12, fish oil, and vitamin B-12+fish oil supplementation lowered plasma Hcy concentrations by 22%, 19%, and 39%, respectively. CONCLUSIONS: The combination of vitamin B-12 and fish oil has a synergistic effect on lowering plasma concentrations of Hcy.
Asunto(s)
Proteína C-Reactiva/efectos de los fármacos , Enfermedades Cardiovasculares/sangre , Ácidos Grasos Omega-3/farmacología , Ferritinas/efectos de los fármacos , Homocisteína/efectos de los fármacos , Vitamina B 12/farmacología , Adulto , China , Suplementos Dietéticos , Ácidos Grasos Omega-3/sangre , Femenino , Ferritinas/sangre , Aceites de Pescado/sangre , Aceites de Pescado/farmacología , Homocisteína/sangre , Humanos , Masculino , Factores de Riesgo , Complejo Vitamínico B/sangre , Complejo Vitamínico B/farmacología , Adulto JovenRESUMEN
BACKGROUND: Hyperhomocysteinemia seems to be a common phenomenon in both patients with ulcerative colitis and Crohn's disease. Many factors including deficiencies of cobalamin, folate and pyridoxine, smoking habits, alcohol and coffee intake, some medications and age may predispose subjects to hyperhomocysteinemia. The study aimed to evaluate homocysteine levels in an inflammatory bowel disease cohort as dependent of life style and disease activity. METHODS: 85 consecutive patients with inflammatory bowel disease (38 with Crohn's disease and 47 with ulcerative colitis) and 65 control subjects were included in the prospective study. The following parameters were analyzed: disease activity, duration of the disease, location of pathological changes, presence of complications, current medications, past surgical procedures, smoking history, concomitant diseases, biochemical parameters and plasma homocysteine levels. RESULTS: Mild hyperhomocysteinemia was found in 16 patients with Crohn's disease (42%), 19 patients with ulcerative colitis (40%) and 19 patients in the control group (29%) (p = 0.59). There was not any significant correlation between homocysteine level and disease activity. Only folic acid supplementation and gender affected homocysteine level. Folic acid intake led to reduction of homocysteine levels in all groups of patients (11.8 micromol/l vs. 8.33 miccromol/l, p = 0.0065 in Crohn's disease patients and 10.94 micromol/l vs. 7.78 micromol/l, p = 0.0069 in ulcerative colitis patients). CONCLUSION: Homocysteine level in patients with inflammatory bowel disease is mostly normal or slightly elevated. Disease activity does not have an impact on homocysteine level. Folic acid is the most important factor having an influence on homocysteine level in patients with inflammatory bowel disease.
Asunto(s)
Ácido Fólico/uso terapéutico , Homocisteína/sangre , Hiperhomocisteinemia/complicaciones , Hiperhomocisteinemia/prevención & control , Enfermedades Inflamatorias del Intestino/sangre , Enfermedades Inflamatorias del Intestino/complicaciones , Adulto , Anciano , Colitis Ulcerosa/sangre , Colitis Ulcerosa/complicaciones , Enfermedad de Crohn/complicaciones , Suplementos Dietéticos , Femenino , Homocisteína/efectos de los fármacos , Humanos , Hiperhomocisteinemia/sangre , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Adulto JovenRESUMEN
Betaine was an endogenous catabolite of choline, which could be isolated from vegetables and marine products. Betaine could promote the metabolism of homocysteine in healthy subjects and was used for hyperlipidemia, coronary atherosclerosis, and fatty liver in clinic. Recent findings shown that Betaine rescued neuronal damage due to homocysteine induced Alzheimer's disease (AD) like pathological cascade, including tau hyperphosphorylation and amyloid-ß (Aß) deposition. Aß was derived from amyloid precursor protein (APP) processing, and was a triggering factor for AD pathological onset. Here, we demonstrated that Betaine reduced Aß levels by altering APP processing in N2a cells stably expressing Swedish mutant of APP. Betaine increased α-secretase activity, but decreased ß-secretase activity. Our data indicate that Betaine might play a protective role in Aß production.
Asunto(s)
Péptidos beta-Amiloides/metabolismo , Precursor de Proteína beta-Amiloide/metabolismo , Betaína/farmacología , Lipotrópicos/farmacología , Secretasas de la Proteína Precursora del Amiloide/metabolismo , Precursor de Proteína beta-Amiloide/genética , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática , Homocisteína/efectos de los fármacos , Humanos , L-Lactato Deshidrogenasa/metabolismo , Ratones , Mutación/genética , Neuroblastoma/patología , TransfecciónRESUMEN
OBJECTIVES: To assess the effect of preventive pravastatin treatment on coronary heart disease (CHD) morbidity and mortality in older persons at risk for cardiovascular disease (CVD), stratified according to plasma levels of homocysteine. DESIGN: A post hoc subanalysis in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), started in 1997, which is a double-blind, randomized, placebo-controlled trial with a mean follow-up of 3.2 years. SETTING: Primary care setting in two of the three PROSPER study sites (Netherlands and Scotland). PARTICIPANTS: Individuals (n = 3,522, aged 70-82, 1,765 male) with a history of or risk factors for CVD were ranked in three groups depending on baseline homocysteine level, sex, and study site. INTERVENTION: Pravastatin (40 mg) versus placebo. MEASUREMENTS: Fatal and nonfatal CHD and mortality. RESULTS: In the placebo group, participants with a high homocysteine level (n = 588) had a 1.8 higher risk (95% confidence interval (CI) = 1.2-2.5, P = .001) of fatal and nonfatal CHD than those with a low homocysteine level (n = 597). The absolute risk reduction in fatal and nonfatal CHD with pravastatin treatment was 1.6% (95% CI = -1.6 to 4.7%) in the low homocysteine group and 6.7% (95% CI = 2.7-10.7%) in the high homocysteine group (difference 5.2%, 95% CI = 0.11-10.3, P = .046). Therefore, the number needed to treat (NNT) with pravastatin for 3.2 years for benefit related to fatal and nonfatal CHD events was 14.8 (95% CI = 9.3-36.6) for high homocysteine and 64.5 (95% CI = 21.4-∞) for low homocysteine. CONCLUSION: In older persons at risk of CVD, those with high homocysteine are at highest risk for fatal and nonfatal CHD. With pravastatin treatment, this group has the highest absolute risk reduction and the lowest NNT to prevent fatal and nonfatal CHD.
Asunto(s)
Enfermedad Coronaria/tratamiento farmacológico , Homocisteína/sangre , Pravastatina/uso terapéutico , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Enfermedad Coronaria/sangre , Enfermedad Coronaria/mortalidad , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Estudios de Seguimiento , Homocisteína/efectos de los fármacos , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Masculino , Países Bajos/epidemiología , Pravastatina/administración & dosificación , Estudios Prospectivos , Escocia/epidemiología , Tasa de Supervivencia/tendencias , Factores de Tiempo , Resultado del TratamientoRESUMEN
INTRODUCTION: Patients with end-stage renal disease are at a high risk of adverse cardiovascular events. Elevated level of homocysteine is an important risk factor for cardiovascular morbidity and mortality in dialysis patients. There are some strategies for reduction of serum homocysteine level in these patients, including folate and vitamin supplementation. The aim of the present study was to evaluate the effect of omega-3 supplementation on serum homocysteine level in patients on hemodialysis. MATERIALS AND METHODS: In a randomized controlled trial, 100 hemodialysis patients were assigned into two groups to receive omega-3 (oral capsule, 3 g/d) or placebo for 2 months. Complete blood count, blood urea nitrogen, serum creatinine, serum lipids, and serum homocysteine levels were measured before the study and after 2 months at the end of study. RESULTS: Of 100 patients, 6 in each group were excluded, and 44 patients in each group completed the study. There were no significant differences regarding the age, sex, and the number of dialysis sessions per week between the two groups. No difference was observed between the two groups in the laboratory investigations at the end of the study, except for a significant reduction in serum homocysteine level in the omega-3 group as compared to the placebo group (P = .03). CONCLUSIONS: Our study showed a significant reduction regulated by omega-3 supplementation in serum homocysteine level which is a cardiovascular risk factor among hemodialysis patients. Omega-3 can be considered as another homocysteine-reducing agent in this population.
Asunto(s)
Suplementos Dietéticos , Ácidos Grasos Omega-3/uso terapéutico , Homocisteína/sangre , Fallo Renal Crónico/sangre , Adolescente , Adulto , Anciano , Recuento de Células Sanguíneas , Nitrógeno de la Urea Sanguínea , Creatinina/sangre , Ácidos Grasos Omega-3/farmacología , Femenino , Homocisteína/efectos de los fármacos , Humanos , Fallo Renal Crónico/terapia , Lípidos/sangre , Masculino , Persona de Mediana Edad , Diálisis Renal , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND & AIMS: Several authors have reported low folate intake in patients with eating disorders (ED). This vitamin plays an essential role in synthesis reactions for neurotransmitters and structural elements of neurons, and therefore its deficiency has been associated with the presence of different disorders linked to mental function. The aim of this study was to determine the effect of folic acid supplementation on homocysteine levels and the cognitive and depressive status of a group of patients with eating disorders with low folate intake. SUBJECTS/METHODS: The study was designed as a randomised, prospective clinical trial, which included 24 participants assigned to two treatment groups for six months: supplemented group (SG) (10 mg/day of folic acid [ACFOL]) and a placebo group (PG). Both groups maintained their medical, dietary and psychological treatment. At baseline and end of the intervention, anthropometric, dietary and biochemical parameters (plasma homocysteine [Hcy], serum and red blood cell folate) were recorded. Cognitive and depressive status questionnaires were administered (Stroop Test, Trail Making Test and Beck Depression Inventory). RESULTS: Twenty-two patients completed the study (SG: 12, PG: 10, mean age: 24.2 ± 8.8 years, BMI 18.9 ± 3.5 kg/m2). The SG significantly increased their serum and red blood cell folate levels and lowered Hcy levels (9.4 ± 2.4 µmol/l vs. 7.5 ± 1.7 µmol/l, P < 0.01). The SG also significantly improved most of their test scores for cognitive and depressive status. The PG showed no significant changes in any of the evaluated variables. CONCLUSIONS: The results show that folic acid supplementation may be used as another tool within the comprehensive and multidisciplinary treatment applied to patients with ED.
Introducción y objetivo: Diferentes autores han reportado una baja ingesta de ácido fólico en pacientes con Trastornos de la Conducta Alimentaria (TCA). Esta vitamina desempeña un papel esencial en las reacciones de síntesis de neurotransmisores y elementos estructurales de las neuronas y, por lo tanto, su deficiencia se ha asociado con la presencia de diferentes trastornos relacionados con la función mental. El objetivo de este estudio fue determinar el efecto de la suplementación con ácido fólico sobre los niveles de homocisteína y sobre marcadores de función cognitiva y depresión en un grupo de pacientes con TCA con baja ingesta de ácido fólico. Sujetos y métodos: Estudio clínico randomizado y prospectivo en el que se incluyeron 24 pacientes asignados a dos grupos de tratamiento durante un período de 6 meses: grupo suplementado (SG) (10 mg/día de ácido fólico [ACFOL®]) y grupo placebo (PG). Ambos grupos mantuvieron su tratamiento médico, dietético y psicológico. Al inicio del estudio y tras la intervención se evaluaron parámetros antropométricos, dietéticos y bioquímicos (homocisteína plasmática [Hcy], folato sérico y eritrocitario). Como marcadores de función cognitiva y depresión se administraron diferentes cuestionarios (Test de Stroop, Trail Making Test, BDI: Cuestionario de percepción de función cognitiva). Resultados: Completaron el estudio 22 pacientes (SG: 12, PG: 10, edad media: 24,2 ± 8,8 años, IMC 18,9 ± 3,5 kg/m2). El grupo SG incrementó de forma significativa sus niveles de folato sérico y eritrocitario y redujo el de homocisteína (9,4 ± 2,4 µmol/l vs. 7,5 ± 1,7 µmol/l, P < 0,01). Además, el grupo SG también mejoró significativamente las puntuaciones de los test de función cognitiva y depresión. En el grupo PG, en cambio, no se observaron cambios significativos en ninguna de las variables evaluadas. Conclusiones: Los resultados obtenidos demuestran que la suplementación con ácido fólico podría emplearse como una herramienta más dentro del complejo y multidisciplinario tratamiento que requieren estos pacientes.